Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amphastar Pharmaceuticals, Inc. - Common Stock (NQ: AMPH )

31.02 -0.72 (-2.27%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amphastar Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
36 Stocks Moving In Thursday's Mid-Day Session
Gainers Powerbridge Technologies Co., Ltd. (NASDAQ: PBTS) jumped 65% to $0.6382. 
Via Benzinga
Amphastar Pharmaceuticals to Present at the Jefferies Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / June 6, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, and Dan Dischner, V.P of Corporate... 
From Amphastar Pharmaceuticals, Inc.
Via AccessWire
Amphastar's Generic Ganirelix Acetate Injection Scores FDA Approval
Via Benzinga
Earnings Scheduled For March 10, 2022
Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares... 
Via Benzinga
Small-Cap Psychedelic Play Vying for Future Leadership in Addiction Treatment (AXSM, AWKNF, BICX, OPNT, ALKS, PFE, AMPH, OMER)
Via AB Newswire
Amphastar Pharmaceuticals's Return On Capital Employed Insights
Pulled from Benzinga Pro data, Amphastar Pharmaceuticals (NASDAQ:AMPH) posted Q1 earnings of $24.25 million, an increase from Q4 of 22.74%. Sales dropped to $120.37 million, a 0.43% decrease between... 
Via Benzinga
United Therapeutics Stock Sees RS Rating Jump To 89; Earns 'Blue Dot'
United Therapeutics stock had its Relative Strength (RS) Rating upgraded to 89 Tuesday, from 71 a day earlier. 
Via Investor's Business Daily
Amphastar Receives FDA Approval for Regadenoson
RANCHO CUCAMONGA, CA / ACCESSWIRE / May 24, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New... 
From Amphastar Pharmaceuticals, Inc.
Via AccessWire
Exposures Product Safety
7 Safe Small-Cap Stocks to Buy Now
If you're looking for resilient plays with high upside potential, consider these seven safe small-cap stocks to buy. 
Via InvestorPlace
Intra-Cellular Therapies Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating
Intra-Cellular Therapies stock cleared a key performance benchmark, with its Relative Strength (RS) Rating, rising to 97. 
Via Investor's Business Daily
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2022
Reports Net Revenues of $120.4 Million for the Three Months Ended March 31, 2022 RANCHO CUCAMONGA, CA / ACCESSWIRE / May 9, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the... 
From Amphastar Pharmaceuticals, Inc.
Via AccessWire
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. 
From Amphastar Pharmaceuticals, Inc.
Via AccessWire
Krystal Biotech Stock Sees Healthy Relative Strength Rating Upgrade
On Thursday, Krystal Biotech stock had its Relative Strength (RS) Rating upgraded from to 93, up 88 a day ago. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
10 Stocks That Have Moved Over 20% Since The Indices Plummeted
The start of 2022 saw a decline in the stock market. For seasoned investors, this was not unexpected, as corrections in the market are commonplace from January through to March.  
Via Benzinga
Why Top-Rated IBD 50 Stock Amphastar Pharmaceuticals Added To Its 75% Run
FDA action just sent this red-hot biotech stock to a high, continuing its strong run. 
Via Investor's Business Daily
Amphastar Receives FDA Approval for Ganirelix Acetate Injection
RANCHO CUCAMONGA, CA / ACCESSWIRE / April 8, 2022 / Amphastar Pharmaceuticals, Inc., (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated... 
From Amphastar Pharmaceuticals, Inc.
Via AccessWire
Exposures Product Safety
Sarepta Therapeutics Stock Shows Market Leadership With Jump To 85 RS Rating
On Thursdays, Sarepta Therapeutics stock had its Relative Strength (RS) Rating upgraded to 85 from 80 a day earlier. 
Via Investor's Business Daily
Supernus Pharmaceuticals Stock Sees Relative Strength Rating Jump To 92
On Thursday, Supernus Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 87 to 92. 
Via Investor's Business Daily
Stocks That Hit 52-Week Highs On Thursday
On Thursday, 75 stocks made new 52-week highs. Interesting Highlights From Today's 52-Week Highs: The largest company by market cap to hit a new 52-week high... 
Via Benzinga
Amphastar Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / April 6, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate... 
From Amphastar Pharmaceuticals, Inc.
Via AccessWire
Apellis Pharmaceuticals Stock Shows Rising Relative Strength
Apellis Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, rising from 87 to 91. 
Via Investor's Business Daily
Acadia Pharmaceuticals Stock Shows Market Leadership With Jump To 91 RS Rating
Acadia Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 88 to 91. 
Via Investor's Business Daily
Biocryst Pharmaceuticals Stock Shows Rising Price Performance With Jump To 92 RS Rating
Biotech Biocryst Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded from 88 to 92 Wednesday. 
Via Investor's Business Daily
7 “A”-Rated Stocks to Ground Your Portfolio
It's a good time to make sure you have "A"-rated stocks in your portfolio. Many of the ones here have my triple-"A" rating. 
Via InvestorPlace
Amphastar Pharmaceuticals: Q4 Earnings Insights
Amphastar Pharmaceuticals (NASDAQ:AMPH) reported its Q4 earnings results on Thursday, March 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2021
Reports Net Revenues of $120.9 Million for the Three Months Ended December 31, 2021 RANCHO CUCAMONGA, CA / ACCESSWIRE / March 10, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or... 
From Amphastar Pharmaceuticals, Inc.
Via AccessWire
Earnings Preview For Amphastar Pharmaceuticals
Amphastar Pharmaceuticals (NASDAQ:AMPH) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement.... 
Via Benzinga
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.